None listed
Conditions
Interventions
Drug : Polydeoxyribonucleotide (Placentex® Integro, 1 ample = 3mL, 5.625mg). The experimental group is treated with PDRN which is injected subcutaneously on the post-operative day (POD) 1. The dose p
Sponsors
Seoul National University Bundang Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients aged 20-60 who were treated with conventional thyroidectomy 2) Subjects who understood and agreed with the purpose and process of the study. 3) Subjects who can follow the visit schedule and the study process.
Exclusion criteria
Exclusion criteria: 1) history of keloid 2) administration or history of administration of systemic steroids, immunesuppressants, chemotherapeutic agents, anticoagulants within two weeks 3) systemic diseases such as diabetes 4) the use of scar-suppressing agents except simple dressing on the surgical site 5) inflammation or infection on the surgical site 6) history of hypersensitivity reaction on PDRN 7) pregnancy or lactiation 8) Subjects who are inappropriate with the study on the investigator's consideration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Modified Vancouver Scar Scale (mVSS) by the investigators;erythema and pigmentation measured by Mexameter® MX 18;skin texture measured by Antera 3D (Miravex©) camera | — |
Secondary
| Measure | Time frame |
|---|---|
| Satisfaction score by questionnaire | — |
Countries
Korea, Republic of
Contacts
Public ContactSOONHYO Kwon
Seoul National University Bundang Hospital
Outcome results
None listed